CN116693668A - 特异性结合至寨卡病毒表位的多特异性抗体及其用途 - Google Patents

特异性结合至寨卡病毒表位的多特异性抗体及其用途 Download PDF

Info

Publication number
CN116693668A
CN116693668A CN202310134988.XA CN202310134988A CN116693668A CN 116693668 A CN116693668 A CN 116693668A CN 202310134988 A CN202310134988 A CN 202310134988A CN 116693668 A CN116693668 A CN 116693668A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310134988.XA
Other languages
English (en)
Chinese (zh)
Inventor
达维德·科尔蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of CN116693668A publication Critical patent/CN116693668A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
CN202310134988.XA 2017-08-31 2018-08-31 特异性结合至寨卡病毒表位的多特异性抗体及其用途 Pending CN116693668A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2017/071891 WO2019042555A1 (en) 2017-08-31 2017-08-31 MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EPPCT/EP2017/071891 2017-08-31
PCT/EP2018/073489 WO2019043166A1 (en) 2017-08-31 2018-08-31 MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN201880057824.9A CN111344302B (zh) 2017-08-31 2018-08-31 特异性结合至寨卡病毒表位的多特异性抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880057824.9A Division CN111344302B (zh) 2017-08-31 2018-08-31 特异性结合至寨卡病毒表位的多特异性抗体及其用途

Publications (1)

Publication Number Publication Date
CN116693668A true CN116693668A (zh) 2023-09-05

Family

ID=59811299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310134988.XA Pending CN116693668A (zh) 2017-08-31 2018-08-31 特异性结合至寨卡病毒表位的多特异性抗体及其用途
CN201880057824.9A Active CN111344302B (zh) 2017-08-31 2018-08-31 特异性结合至寨卡病毒表位的多特异性抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880057824.9A Active CN111344302B (zh) 2017-08-31 2018-08-31 特异性结合至寨卡病毒表位的多特异性抗体及其用途

Country Status (21)

Country Link
US (2) US11926658B2 (enExample)
EP (1) EP3676290A1 (enExample)
JP (2) JP7244489B2 (enExample)
KR (1) KR20200042499A (enExample)
CN (2) CN116693668A (enExample)
AU (1) AU2018322842A1 (enExample)
BR (1) BR112020000619A2 (enExample)
CA (1) CA3070780A1 (enExample)
CL (1) CL2020000467A1 (enExample)
CO (1) CO2020002060A2 (enExample)
CR (1) CR20200087A (enExample)
DO (1) DOP2020000043A (enExample)
EA (1) EA202090559A1 (enExample)
EC (1) ECSP20014362A (enExample)
IL (1) IL271515A (enExample)
MX (1) MX2020002181A (enExample)
MY (1) MY201774A (enExample)
PE (1) PE20200888A1 (enExample)
PH (1) PH12020550025A1 (enExample)
SG (1) SG11202000206SA (enExample)
WO (2) WO2019042555A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019042555A1 (en) * 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
WO2019090233A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
JP7443233B2 (ja) 2017-11-30 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
CN114907456B (zh) * 2019-11-07 2025-05-30 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
JP2023526493A (ja) * 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2021236225A1 (en) * 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN114958747B (zh) * 2022-06-08 2024-08-20 中国科学院动物研究所 一种多能干细胞诱导产生兴奋性和抑制性神经元的方法
WO2025107050A1 (pt) * 2023-11-23 2025-05-30 Imunotera Soluções Terapêuticas Ltda Anticorpo monoclonal, vetor de expressão, uso, composição farmacêutica, processo para produção, método de prevenção e/ou tratamento de infecções por flavivírus e kit para a detecção de vírus da zika e da dengue
CN119119256B (zh) * 2024-09-28 2025-07-18 宁波大学 一种乙型脑炎病毒和寨卡病毒的单克隆抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
RU2016129959A (ru) 2013-12-30 2018-02-02 Эпимаб Биотерепьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
EP2980099A1 (en) * 2014-07-31 2016-02-03 Bernhard-Nocht-Institut für Tropenmedizin Compositions and methods for detecting flaviviridae infections
UA126548C2 (uk) 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
US20190194260A1 (en) 2016-03-11 2019-06-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Live attenuated zika virus vaccine
CN105954512A (zh) 2016-06-01 2016-09-21 卢氏实验室公司 一种快速免疫层析法检测塞卡病毒Zika virus的检测条
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
TW201815821A (zh) * 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
CN106279409B (zh) 2016-08-10 2019-11-26 中国科学院微生物研究所 一种寨卡病毒人源单克隆抗体及其应用
WO2018081755A1 (en) * 2016-10-29 2018-05-03 University Of Miami Zika virus antibodies
EP3534953A4 (en) * 2016-11-02 2020-10-07 Vanderbilt University ANTIBODIES AGAINST HUMAN ZIKA VIRUS AND THEIR USE PROCEDURES
CN106841601A (zh) 2016-12-30 2017-06-13 广州市达瑞生物技术股份有限公司 寨卡病毒多片段融合蛋白的制备及IgG/IgM抗体检测试剂盒
CN106885903B (zh) 2017-03-08 2018-12-28 中国人民解放军军事医学科学院基础医学研究所 一种寨卡病毒e抗原及其在检测抗寨卡病毒抗体中的应用
WO2019042555A1 (en) * 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF

Also Published As

Publication number Publication date
JP2023071956A (ja) 2023-05-23
BR112020000619A2 (pt) 2020-07-14
IL271515A (en) 2020-02-27
WO2019042555A1 (en) 2019-03-07
PE20200888A1 (es) 2020-09-03
CO2020002060A2 (es) 2020-06-09
CL2020000467A1 (es) 2020-06-19
EA202090559A1 (ru) 2020-06-17
ECSP20014362A (es) 2020-04-22
AU2018322842A1 (en) 2020-01-16
JP2020531000A (ja) 2020-11-05
CN111344302A (zh) 2020-06-26
US11926658B2 (en) 2024-03-12
PH12020550025A1 (en) 2021-02-15
KR20200042499A (ko) 2020-04-23
JP7244489B2 (ja) 2023-03-22
CN111344302B (zh) 2023-03-10
DOP2020000043A (es) 2020-09-15
WO2019043166A1 (en) 2019-03-07
CR20200087A (es) 2020-08-07
EP3676290A1 (en) 2020-07-08
US20200317755A1 (en) 2020-10-08
MY201774A (en) 2024-03-16
US20240254207A1 (en) 2024-08-01
CA3070780A1 (en) 2019-03-07
SG11202000206SA (en) 2020-03-30
MX2020002181A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
US11912757B2 (en) Antibodies specifically binding to Zika virus epitopes and uses thereof
US20240254207A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
US11390664B2 (en) Antibodies that potently neutralize hepatitis B virus and uses thereof
EP2374816B1 (en) Binding molecules against Chikungunya virus and uses thereof
HK40025147B (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
HK40025147A (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
HK40002097B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK40002097A (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
EA046175B1 (ru) Выделенное антитело или его антигенсвязывающий фрагмент, которые специфически связываются с эпитопом вируса зика, их получение и применения
EA043940B1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
BR122024006890A2 (pt) Anticorpo isolado, ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, vetor, célula, composição farmacêutica, uso dos mesmos, kit de partes, bem como ensaio de bloqueio de ligação para diagóstico in vitro de infecção por zika vírus
HK40006233B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK40006233A (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination